Pharmaceuticals, Biotechnology and Life Sciences
Swedish Medivir said Monday that positive data from the investigator-initiated study of remetinostat in basal cell carcinoma (BCC) patients has shown that remetinostat gel offers a potentially effective and well-tolerated, non-surgical intervention for treatment of localized BCCs.
Transgene can start linical trial of its lead myvac™ candidate TG4050as a potential treatment for ovarian cancer patients after first-linesurgery and chemotherapy
PARIS–(BUSINESS WIRE)–The first edition of the HealthTech Investor Days (HTID) will take place in Paris on June 24th and 25th…
Kraig Labs opens R&D headquarters to media for the first time ANN ARBOR, Mich.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24KBLB&src=ctag" target="_blank"gt;$KBLBlt;/agt; lt;a href="https://twitter.com/hashtag/KBLB?src=hash" target="_blank"gt;#KBLBlt;/agt;–Kraig…
TransPerfectLife Sciences, a leading provider of services and technologies tosupport global product development for the life sciences industry, hasreleased version 1.2 of myTI,the mobile application that enables real-time eTMF management andoversight for study teams on the go.
phase-II AMBER study whichdemonstrated that a significantly higher proportion of patients withresistant hypertension (RHTN) and chronic kidney disease (CKD) takingVeltassa® (patiromer) remained on spironolactone therapycompared to patients taking placebo at week 12.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) todayannounced the launch of a generic version of Delzicol®1(mesalamine) delayed-release capsules, 400 mg, in the U.S.
Global oligonucleotide synthesis market is expected to reach $2.9billion by 2024, at a CAGR of 10.5% during the forecast period of 2019to 2024.
MONROE, N.C.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/hospital?src=hash" target="_blank"gt;#hospitallt;/agt;–Greiner Bio-One is pleased to announce the launch of the newly redesigned MiniCollect® K2EDTA Capillary Collection…
FDA) has granted Breakthrough Therapy Designation forSEP-363856, a novel agent for the treatment of people with schizophrenia.